V-Wave nabs FDA breakthrough designation for its heart pressure shunt implant

E-Tattoo takes the hassle out of heart monitoring
Currently, V-Wave’s device is being evaluated in a randomized trial set to enroll 500 patients with advanced heart failure. (Pixabay)

V-Wave has received a breakthrough device designation from the FDA for its interatrial shunt being tested for heart failure.

Implanted through a minimally invasive procedure, the biocompatible device creates a passageway connecting the heart’s two atria. By allowing excess blood to flow between the chambers, the shunt is designed to help regulate high pressure in the left atrium, which can lead to the buildup of fluid in the lungs and difficulty breathing.

Currently, V-Wave’s device is being evaluated in a randomized trial set to enroll 500 patients with advanced heart failure that are still symptomatic following other drug and device therapies, including patients with preserved or reduced left ventricular ejection fraction. The study is expected to return data in late 2021.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

In addition to the extra face time with federal regulators that the FDA designation affords during development and prioritized review, the Centers for Medicare and Medicaid Services recently finalized ways to expedite reimbursement for breakthrough products following approval.

RELATED: V-Wave nets $70M in Series C financing for its heart shunt device

“The potential for early CMS support for this program makes our Breakthrough Designation a double-win for [heart failure] patients who need access to novel therapies as quickly as possible,” V-Wave CEO Neal Eigler said in a statement.

The Israel-based V-Wave raised $70 million for its efforts last year, in a series C round led by Deerfield Management. Its previous backers also include Johnson & Johnson Innovation and Edwards Lifesciences.

"More than 6 million people suffer from chronic heart failure in the US. HF remains a leading cause of acute hospitalization in the Medicare age group,” said William Abraham, V-Wave’s chief medical officer.

“Despite decades of advances in therapy, heart failure patients continue to deteriorate, enduring disabling symptoms, having a poor quality of life, diminished exercise tolerance, and a markedly reduced life expectancy,” Abraham said, pointing to fluid buildup in the lungs as one of the most common reasons for heart failure hospitalizations.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.